This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
1 Nov 2010

Almirall, Forest COPD drug misses goal in PhIII study

Spain's Laboratorios Almirall fell the most in two years after results from a study of aclidinium bromide showed a smaller benefit for patients.

Spain's Laboratorios Almirall fell the most in two years after results from a study of aclidinium bromide, an investigative bronchodilator, showed a smaller benefit for patients what had been observed in previous studies, Bloomberg reports. Almirall is partnered with Forest Laboratories on the product.

The ACCORD COPD II study in 544 patients with moderate to severe COPD is the second of three double-blind, placebo-controlled Phase III studies investigating twice-daily aclidinium bromide, 200 and 400 ug. The drug did seem to help patients; however, for the expected therapeutic dose, 400 ug, the magnitude of effect compared with placebo was less than that observed in three other studies.


If approved, the product would compete with  Boehringer Ingelheim's Spiriva. The disappointing results follow a similar announcement in September 2008 that Almirall's drug hadn't matched the effect shown in previous trials, says Francisco Salvador, a Madrid-based strategist a

Related News